Systemic Adjuvant Treatment of T1a and T1b NOMO HER2+Breast Carcinomas; an AERIO/UNICANCER Study.

被引：0
|
作者：
Peron, J. [1 ]
Vano, Y. [1 ]
Frenel, J-S [1 ]
Wassermann, J. [1 ]
Albiges, L. [1 ]
Rodrigues, M. J. [1 ]
Cottu, P. H. [1 ]
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P2-18-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-18-03
引用
收藏
页数：1
相关论文
共 50 条
  • [21] What is the most common mammographic appearance of T1a and T1b invasive breast cancer?
    Podkrajsek, Maja
    Zgajnar, Janez
    Hocevar, Marko
    RADIOLOGY AND ONCOLOGY, 2008, 42 (04) : 173 - 180
  • [22] Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer
    Fasano, Genevieve A.
    Bayard, Solange
    Chen, Yalei
    Varella, Leticia
    Cigler, Tessa
    Bensenhaver, Jessica
    Simmons, Rache
    Swistel, Alexander
    Marti, Jennifer
    Moore, Anne
    Andreopoulou, Eleni
    Ng, John
    Brandmaier, Andrew
    Formenti, Silvia
    Ali, Haythem
    Davis, Melissa
    Newman, Lisa
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (01) : 163 - 173
  • [23] Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer
    Genevieve A. Fasano
    Solange Bayard
    Yalei Chen
    Leticia Varella
    Tessa Cigler
    Jessica Bensenhaver
    Rache Simmons
    Alexander Swistel
    Jennifer Marti
    Anne Moore
    Eleni Andreopoulou
    John Ng
    Andrew Brandmaier
    Silvia Formenti
    Haythem Ali
    Melissa Davis
    Lisa Newman
    Breast Cancer Research and Treatment, 2022, 192 : 163 - 173
  • [24] SHOULD MULTIFOCAL PAPILLARY THYROID CARCINOMAS CLASSIFIED AS T1A WITH A TUMOR DIAMETER SUM OF 1 TO 2 CENTIMETERS BE RECLASSIFIED AS T1B?
    Tam, Abbas Ali
    Ozdemir, Didem
    Ogmen, Berna Evranos
    Faki, Sevgul
    Dumlu, Ersin Gurkan
    Yazgan, Aylin Kilic
    Ersoy, Reyhan
    Cakir, Bekir
    ENDOCRINE PRACTICE, 2017, 23 (05) : 526 - 535
  • [25] The prognosis of T1a, T1b N0 M0, HER2+patients in Korea
    Lee, J. W.
    Moon, H-G
    Han, W.
    Noh, D-Y
    CANCER RESEARCH, 2012, 72
  • [26] Are We Overtreating Patients With T1a HER2+Breast Cancer? An Analysis of the National Cancer Database
    Williams, Austin D.
    Solis, Odette
    Sterbling, Helene M.
    Murray, Allison
    Sogunro, Olutayo
    De la Cruz, Lucy M.
    CLINICAL BREAST CANCER, 2022, 22 (08) : 828 - 839
  • [27] Predictive factors of axillary lymph node metastasis in early (T1a and T1B) breast cancer
    Ali, I
    Witkiewicz, A
    Jaratli, H
    Edmiston, K
    Khan, A
    MODERN PATHOLOGY, 2002, 15 (01) : 25A - 25A
  • [28] Predictive factors of axillary lymph node metastasis in early (T1a and T1b) breast cancer
    Ali, I
    Witkiewicz, A
    Jaratli, H
    Edmiston, K
    Khan, A
    LABORATORY INVESTIGATION, 2002, 82 (01) : 25A - 25A
  • [29] Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b
    Masue, N
    Deguchi, T
    Nakano, M
    Ehara, H
    Uno, H
    Takahashi, Y
    INTERNATIONAL JOURNAL OF UROLOGY, 2005, 12 (12) : 1045 - 1049
  • [30] Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: Validation of the UICC T1 subgroup classification
    Ichizawa, N
    Fukutomi, T
    Iwamoto, E
    Akashi-Tanaka, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (03) : 108 - 109
12345